CClinicalTrials.gg
TerminatedNCT06002971Updated Mar 5, 2026

CONNEQT Pulse Validation Study

An observational study in Pregnancy Related, Pre-Eclampsia and Gestational Hypertension, sponsored by Mount Carmel Health System. Terminated at 1 site in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-05.

Sponsored by Mount Carmel Health System · Observational

Why this study was terminated
Unable to recruit intended patient population
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
41
Ages
18 Years and older
Sex
Female
01

Study summary

The purpose of this study is to validate the accuracy of the CONNEQT Pulse blood pressure monitoring system for the measurement of blood pressure as compared to a gold standard, auscultatory sphygmomanometer in a pregnant population.

Read the detailed description

Clinical staff will review patient's medical record to determine eligibility. Following informed consent, a brief medical history will be collected. Serial blood pressure measurements will be collected to compare an auscultatory sphygmomanometer to blood pressure measurements of the CONNEQT Pulse blood pressure monitoring system in a pregnant population according to ISO protocol 81060-2.

02

Conditions studied

  • Pregnancy Related
  • Pre-Eclampsia
  • Gestational Hypertension
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Pregnant patients 18 years or older and beyond the first trimester, as defined as 12 completed weeks of gestation.

Eligibility criteria

All Groups:

  1. Able to provide informed consent
  2. Pregnant patient, beyond the first trimester (greater than 12 weeks of gestation)
  3. 18 years of age, or older

Normotensive:

1. Systolic blood pressure \<140 mmHg (18,66 kPa) and diastolic blood pressure \<90 mmHg (12 kPa)

Hypertensive:

  1. Without proteinuria >300 mg in 24 h; and
  2. With systolic blood pressure ≥140 mmHg (18,66 kPa) or diastolic blood pressure ≥ 90 mmHg (12 kPa)

Pre-Eclampsia:

  1. With proteinuria >300 mg in 24 h; and
  2. With systolic blood pressure ≥140 mmHg (18,66 kPa) or diastolic blood pressure ≥ 90 mmHg (12,00 kPa)
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
41 participants (actual)
Patient registry
No

Groups and cohorts

  • Normotensive

    Normotensive pregnant patients beyond the first trimester with systolic blood pressure \<140 mmHg and diastolic blood pressure \<90 mmHg

    Device: Blood pressure measurement

  • Hypertensive

    Hypertensive pregnant patients beyond the first trimester: i) without proteinuria \>300 mg in 24 h; and ii) with systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥ 90 mmHg

    Device: Blood pressure measurement

  • Pre-Eclampsia

    Pre-eclampsia patients beyond the first trimester: i) with proteinuria \>300 mg in 24 h; and ii) with systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥ 90 mmHg

    Device: Blood pressure measurement

Interventions

  • DeviceBlood pressure measurement

    Serial blood pressure measurements to compare reference auscultatory sphygmomanometer to CONNEQT Pulse according to ISO 81060-2.

05

What researchers measure

Primary outcomes

  1. Comparison of reference auscultatory blood pressure readings to CONNEQT Pulse blood pressure readings.

    Paired means and standard deviations of both systolic and diastolic blood pressure readings will be analyzed according to section 5.2.4.1.2 of ISO 81060-2 protocol.

    Time frame: Up to 60 minutes

06

Study locations

1 site
  • Mount Carmel East
    Columbus, Ohio 43213, United States
07

Registry details

Key details

Study ID
NCT06002971
Lead sponsor
Mount Carmel Health System
Collaborators
AtCor Medical, Inc.
Responsible party
Robin Driver (Principal Investigator, Mount Carmel Health System) — Principal investigator
First posted
Aug 21, 2023
Start date
Aug 21, 2023
Primary completion
Jun 3, 2025
Completion
Jun 3, 2025
Last update
Mar 5, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion